Therefore, the study was amended so that the pharmacodynamic consequences of single-agent pazopanib treatment could be explored through quantitation of total and phosphorylated c-MET in paired tumor biopsies; longitudinal analyses of plasma levels of circulating HGF, c-MET, VEGFR2, and VEGF were examined during pazopanib + tivantinib combination treatment. This evidence concerns the gene HGF and neoplasm.